Other news
Celebrating six years of PREMIER: Final Event and General Assembly in Cambridge17 June 2026 - 10:41
New scientific paper: Defining the data gap: What do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?26 March 2026 - 10:58
New scientific paper: Intelligent consensus predictions of bioconcentration factor of pharmaceuticals using 2D and fragment-based descriptors26 March 2026 - 10:58
Meet our Scientific Advisory Board: interview with Johannes Kirchmair25 March 2026 - 14:16
Invitation for the PREMIER Final Event, 9 June 2026, Cambridge, UK19 March 2026 - 16:13
The transition towards sustainable pharmaceuticals – assessing sustainability, from design & production to prescription & use
blog, GeneralPrioritization and selection of APIs using a risk-based approach
blogBy Cristiana Cannata, PhD researcher in Environmental Science at Radboud University (Nijmegen, The Netherlands) & contributor of PREMIER WP1.2 There are more than 1500 active pharmaceutical ingredients (APIs) on the European market. Residues of these APIs can eventually reach the environment and given the enormous number of human medicines being used, it is unclear which […]
Ecotoxicity testing: guidelines and evaluation
blogBy Alice Marshall, PhD researcher in Environmental Toxicology at University of York & contributor of PREMIER WP2.1; and Caroline Moermond, Sr Policy Advisor at the National Institute for Public Health and the Environment (RIVM), lead of PREMIER WP4 and contributor of WP3. With the continuous development of new and existing pharmaceuticals, investigation into the environmental legacy of active pharmaceutical […]